Reduces the risk of recurrence in patients in remission
In Italy, about 3,600 people are affected every year by acute myeloid leukemia, a blood cancer that has the highest incidence in the over 65s. It is a particularly aggressive haematological disease, in fact the 5-year survival depends , fluctuates between 20% and 40-45% and does not exceed 12 months for patients with relapsed or refractory disease. Indeed, responses to intensive chemotherapy can be short-lived and the risk of recurrence is high, especially for people ineligible for stem cell transplantation. Today the standard of care is changing, thanks to a new hypomethylating drug, oral azacitidine, capable of improving survival by reducing the probability of recurrence. The Italian Medicines Agency (AIFA) has approved the reimbursement of oral azacitidine as maintenance therapy in patients who have achieved a … (Continue) read the 2nd page
News about: leukemia, azacitidine, cells, Azacitidine for acute myeloid leukemia Reduces the risk of relapse in patients in remission
Multiple myeloma, ciltacabtagene autoleucel effective New promising results in early lines of therapy
Leukemia, approved ivosidenib Drug also indicated for cholangiocarcinoma
The treatments of Chronic Lymphatic Leukemia The various stages of the treatment process
Leukemia, a new tool to predict its evolution The probability that a myelodysplastic syndrome evolves into leukemia
Acute myeloid leukemia, what recurrences depend on Responsible stem cells identified
Carcik cells for acute myeloid leukemia New enhanced version of the therapy
Acute myeloid leukemia, new therapy increases survival The drug venetoclax indicated in the most difficult cases
Leukemia, ibrutinib plus venetoclax effective Efficacy and durable responses from fixed-duration treatment
Acute lymphoblastic leukemia, ponatinib effective For adult patients with Philadelphia-positive leukemia
Leukemia, the healthy microbiota improves therapy The higher the chances of surviving the disease
Leukemia, new markers discovered They indicate the progression of the disease
Leukemia, effective zanubrutinib Response rate higher than ibrutinib
Leukemia, here’s how it resists therapy Molecular “silencer” discovered that hides it from the immune system
Leukemia improves survival after transplantation Recurrence remains the leading cause of transplant failure
Acute myeloid leukemia, gilteritinib effective For patients who carry mutations in the FLT3 gene
Acute myeloid leukemia, engineered lymphocytes are effective First clinical trial of the innovative cell therapy
10 years without leukemia thanks to CAR-T The cases of 2 patients treated in 2010
Chronic lymphocytic leukemia, available acalabrutinib The new therapy improves the quality of life